Top 3 drug approvals in November: Opdivo^®, Adcetris^® and Brukinsa^®

In November, we saw a wave of approvals, extending treatment options for various cancer types. NICE (UK) granted several approvals, including Exkivity® (mobocertinib) for EGFR exon 20 insertion gene mutation-positive advanced NSCLC, Cabometyx® (cabozantinib) for advanced hepatocellular carcinoma, Keytruda (pembrolizumab) neoadjuvant and adjuvant treatment of early and locally advanced non-metastatic TNBC as well as Opdivo® (nivolumab) for certain gastroesophageal cancer subtypes. Find out further details on that final approval, plus approvals from the European Commission and US FDA by checking out our drug approval highlights below. ADCETRIS® (brentuximab vedotin) Approved: 10 November 2022 Approving body: US FDA Indication: Childhood classical...